we performed whole exome sequencing (WES) of plasma cell free (cfDNA) and matched germline DNA in patients with CT-detected pulmonary lesions to determine the feasibility of somatic cfDNA mutations to ...

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

The next-generation sequencing market valued at US$ 13.92 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, ...

Currently, next-generation sequencing can be used in clinical scenarios detecting CNVs, and the use of exome sequencing in the DD cohort ahead of the microarray test has not been evaluated. Methods ...

Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received ...

Natera CEO Steve Chapman provided updates on the firm's new product launches and clinical evidence generation within its cancer business. First, the firm has launched a new version of Signatera using ...

The US company said that results from the Alpha-CORRECT trial saw its colon cancer diagnostic Oncodetect achieving a ...

New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients ...

technologies have significantly enhanced the ability to sequence cancer-related genes in clinical settings. As NGS continues to evolve, its role in personalized and targeted cancer therapies ...